Aktis Oncology, Inc. (AKTS)
| Market Cap | 793.00M |
| Revenue (ttm) | 5.56M |
| Net Income (ttm) | -60.65M |
| Shares Out | 46.65M |
| EPS (ttm) | -1.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AKTS
Aktis Oncology is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. We see a significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope. To ensure patient dema... [Read more]
News
Aktis Oncology files for US IPO as biotech listings rebound
Aktis Oncology filed for an initial public offering in the United States on Friday, as stock market listings from the biotech industry rebound after a slowdown.
Phase 1 solid tumor biotech Aktis Oncology files for a $100 million IPO
Aktis Oncology, a Phase 1 biotech developing targeted radiopharmaceuticals to treat solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Aktis Oncology IPO Registration Document (S-1)
Aktis Oncology has filed to go public with an IPO on the NASDAQ.